{"protocolSection":{"identificationModule":{"nctId":"NCT03462446","orgStudyIdInfo":{"id":"18231"},"organization":{"fullName":"Bayer","class":"INDUSTRY"},"briefTitle":"Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events","officialTitle":"Estimate of Costs Associated With Atrial Fibrillation Treatment With Rivaroxaban Versus Vitamin K Antagonists"},"statusModule":{"statusVerifiedDate":"2018-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-06-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2016-05-01","type":"ACTUAL"},"completionDateStruct":{"date":"2016-05-01","type":"ACTUAL"},"studyFirstSubmitDate":"2018-02-26","studyFirstSubmitQcDate":"2018-03-09","studyFirstPostDateStruct":{"date":"2018-03-12","type":"ACTUAL"},"lastUpdateSubmitDate":"2018-03-09","lastUpdatePostDateStruct":{"date":"2018-03-12","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bayer","class":"INDUSTRY"},"collaborators":[{"name":"Janssen Research & Development, LLC","class":"INDUSTRY"}]},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The main objective of this project is to evaluate savings in direct costs as regards the use of rivaroxaban versus vitamin K antagonists (VKAs) in routine clinical practice using data from three cohorts of patients receiving VKAs or rivaroxaban in Spain, including the time in therapeutic range (TTR) values of the same and the incidence of events in the first year following diagnosis."},"conditionsModule":{"conditions":["Atrial Fibrillation"],"keywords":["Atrial fibrillation","VKA","Stroke"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"RETROSPECTIVE"},"enrollmentInfo":{"count":249,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Treatment group with Rivaroxaban","description":"Patients treated with Rivaroxaban","interventionNames":["Drug: Rivaroxaban (Xarelto, BAY59-7939)"]},{"label":"Control group with VKAs","description":"Patients treated with VKAs. This control group will be subsequently divided based on the TTR value in the last 6 months (below 65% and above 65%).","interventionNames":["Drug: Vitamin K antagonists (VKAs)"]}],"interventions":[{"type":"DRUG","name":"Rivaroxaban (Xarelto, BAY59-7939)","description":"As prescribed by treating physicians","armGroupLabels":["Treatment group with Rivaroxaban"]},{"type":"DRUG","name":"Vitamin K antagonists (VKAs)","description":"As prescribed by treating physicians. VKAs are Acenocoumarol and Warfarin.","armGroupLabels":["Control group with VKAs"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Time in therapeutic range (TTR) values in the last 6 months","timeFrame":"6 months"},{"measure":"Presence of stroke","description":"Presence of stroke prior and subsequent to treatment","timeFrame":"12 months"},{"measure":"Active substance received","description":"Rivaroxaban or VKAs (Acenocoumarol and Warfarin)","timeFrame":"12 months"}],"secondaryOutcomes":[{"measure":"Date of stroke","timeFrame":"12 months"},{"measure":"Type of stroke","description":"Type of stroke acccording to patients group: unknown, haemorrhagic or ischaemic.","timeFrame":"12 months"},{"measure":"Duration of treatment (in days)","timeFrame":"12 months"},{"measure":"Dose of the prescribed treatment","timeFrame":"12 months"},{"measure":"Frequency of the prescribed treatment (in hours)","timeFrame":"12 months"}],"otherOutcomes":[{"measure":"Date of AF diagnosis","timeFrame":"12 months"},{"measure":"Comorbidities","timeFrame":"12 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Older than 18 years\n* Diagnosis of non-valvular AF (ICD code 427.31)\n* Pharmacological treatment with VKAs or rivaroxaban following diagnosis\n\nExclusion Criteria:\n\n-","sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Selected population will include records registered in electronic databases of patients diagnosed with nonvalvular AF, receiving treatment with VKAs or rivaroxaban for one year.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Bayer Study Director","affiliation":"Bayer","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Granada","country":"Spain","geoPoint":{"lat":37.18817,"lon":-3.60667}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000014812","term":"Vitamin K"},{"id":"D000069552","term":"Rivaroxaban"}],"ancestors":[{"id":"D000014815","term":"Vitamins"},{"id":"D000018977","term":"Micronutrients"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000065427","term":"Factor Xa Inhibitors"},{"id":"D000000991","term":"Antithrombins"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000925","term":"Anticoagulants"},{"id":"D000000933","term":"Antifibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000006490","term":"Hemostatics"},{"id":"D000003029","term":"Coagulants"}],"browseLeaves":[{"id":"M17245","name":"Vitamin K","asFound":"Black","relevance":"HIGH"},{"id":"M17248","name":"Vitamins","relevance":"LOW"},{"id":"M463","name":"Rivaroxaban","asFound":"Weight loss","relevance":"HIGH"},{"id":"M17292","name":"Warfarin","relevance":"LOW"},{"id":"M1271","name":"Acenocoumarol","relevance":"LOW"},{"id":"M20699","name":"Micronutrients","relevance":"LOW"},{"id":"M16575","name":"Trace Elements","relevance":"LOW"},{"id":"M30203","name":"Factor Xa Inhibitors","relevance":"LOW"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3996","name":"Antithrombin III","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"M3942","name":"Antifibrinolytic Agents","relevance":"LOW"},{"id":"M9266","name":"Hemostatics","relevance":"LOW"},{"id":"M5949","name":"Coagulants","relevance":"LOW"},{"id":"T481","name":"Vitamin K","asFound":"Black","relevance":"HIGH"},{"id":"T450","name":"Menaquinone","relevance":"LOW"},{"id":"T449","name":"Menadione","relevance":"LOW"},{"id":"T452","name":"Naphthoquinone","relevance":"LOW"},{"id":"T458","name":"Phylloquinone","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"Micro","name":"Micronutrients"},{"abbrev":"Coag","name":"Coagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"Vi","name":"Vitamins"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":false}